Mindray Medical (MR) Tops Q3 EPS by 2c

Mindray Medical (NYSE: MR) reported Q3 EPS of $0.46, $0.02 better than the analyst estimate of $0.44. Revenue for the quarter came in at $324.6 million versus the consensus estimate of $334.5 million.

"In the third quarter, we are delighted to see our sales in China and Western Europe achieving double-digit growth. Nevertheless, we experienced sustained softness in some of our key emerging markets as a result of unfavorable currency fluctuations and political tensions," commented Mr. Li Xiting, Mindray's President and Co-Chief Executive Officer. "In addition, our reagents as well as the high-end hematology and high-speed biochemistry analyzers performed well in China. This reflects our success in introducing high-end products to grow the recurring revenue stream in our IVD segment."

For earnings history and earnings-related data on Mindray Medical (MR) click here.

You May Also Be Interested In

• Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
• Small stocks still very cheap vs. large - BofA
• Tesla (TSLA) pivoting back towards cheap EV cars 'raises more questions' - Deutsche Bank